Skip Navigation
Department of Health and Human Services
Slide Tray
0 slides

Return to Slide Library


Add Presentation to Slide Tray Presentation:

Management of the Patient with Stable Ischemic Heart Disease and Preserved Left Ventricular Systolic Function

Slide: 5 of 21

Pharmacologic Effects of Antagonists on the Renin-Angiotensin-Aldosterone System

Despite standard therapy, patients with stable ischemic heart disease and preserved left ventricular systolic function continue to be at risk for future cardiovascular events. The Renin-Angiotensin-Aldosterone System (RAAS) is critical for regulating blood pressure, electrolyte balance, and fluid volume homeostasis and plays a pivotal role in the pathogenesis of hypertension, congestive heart failure, and diabetic nephropathy. Pharmacological antagonists of this system include angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II-receptor blockers (ARBs). These drugs block adverse effects of the RAAS by blocking the activity of angiotensin II through different mechanisms:

ACEIs act on the RAAS by blocking the conversion of angiotensin I into angiotensin II and inhibiting the breakdown of bradykinin, which is a potent vasodilator.

ARBs block the angiotensin II type-1 receptor and reduce the pharmacologic effects of angiotensin II, regardless of whether angiotensin II is created by the angiotensin-converting enzyme or by pathways independent of this enzyme.

ACEIs and ARBs may potentially provide several pharmacological effects over and above that of blood pressure reduction alone, which may impact cardiovascular events.

Through angiotensin II type-1 receptors, angiotensin II may have these potentially harmful activities:

  1. Induction of aldosterone production, which can cause sodium retention and increased fluid retention that may lead to increased blood pressure.
  2. Increased aldosterone production, which can lead to pathogenic remodeling (i.e., atherosclerosis and fibrosis).
  3. Constriction of blood vessels, which can lead to increased blood pressure.
  4. Potential reduction in the availability of nitric oxide through the production of free radicals and the induction of endothelial dysfunction that may impact endothelial wall integrity.